FRE.DE - Fresenius SE & Co. KGaA

XETRA - XETRA Delayed Price. Currency in EUR
65.00
+0.30 (+0.46%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close64.70
Open64.44
Bid0.00 x 120700
Ask0.00 x 6100
Day's Range64.38 - 65.66
52 Week Range58.96 - 72.76
Volume1,085,806
Avg. Volume1,292,772
Market Cap36.059B
Beta0.81
PE Ratio (TTM)20.17
EPS (TTM)3.22
Earnings DateOct 30, 2018
Forward Dividend & Yield0.75 (1.08%)
Ex-Dividend Date2018-05-22
1y Target EstN/A
  • Helping an Execution Is a Bad Look for a Drugmaker
    Bloombergyesterday

    Helping an Execution Is a Bad Look for a Drugmaker

    The German drug manufacturer Fresenius Kabi is suing to block an execution in Nebraska — not because it opposes capital punishment, but because it would be bad for the company’s public relations for its drugs to be used to kill. Other drug companies have also tried to block executions using their products for similar reasons. A federal district judge rejected Fresenius’s suit Friday, but the company has appealed.

  • Thomson Reuters StreetEvents7 days ago

    Edited Transcript of FRE.DE earnings conference call or presentation 31-Jul-18 12:00pm GMT

    Q2 2018 Fresenius SE & Co KGaA Earnings Call

  • Reuters14 days ago

    Akorn row overshadows Fresenius' generics guidance

    Fears that a legal dispute with U.S. drugmaker Akorn could extend into next year overshadowed improved guidance from Germany's Fresenius SE for its Kabi generics business. Akorn is suing Fresenius for walking away from a $4.7 billion takeover agreement in April and the uncertainty over the outcome of the trial is hanging over the stock. Chief Executive Stephan Sturm told analysts Fresenius stood by its decision to pull out of the deal after uncovering data integrity breaches at Akorn which he says were systemic.

  • Associated Press14 days ago

    Fresenius: 2Q Earnings Snapshot

    The Bad Homburg, Germany-based company said it had net income of $1.94 per share. Earnings, adjusted for non-recurring gains, were 54 cents per share. The dialysis services provider posted revenue of $5.03 ...

  • Reuters21 days ago

    German clinic chain Median put up for sale -sources

    Dutch private equity group Waterland is launching the sale of Median Kliniken, Germany's largest private-sector chain of post-acute care clinics, in a deal potentially worth more than 1 billion euros ($1.17 billion), people close to the matter said. The sellside advisor Morgan Stanley is expected to send out information packages to prospective bidders in the autumn, they said, adding that first meetings with potential suitors are already taking place. Berlin-based Median operates some 120 healthcare facilities and is expected to post adjusted earnings before interest, tax, depreciation and amortization of about 100-120 million euros this year.

  • Akorn Fell 6.8% on July 13, Fresenius-Akorn Merger Woes Continue
    Market Realist29 days ago

    Akorn Fell 6.8% on July 13, Fresenius-Akorn Merger Woes Continue

    On July 13, Akorn (AKRX) shares fell ~6.8% and closed at $17.91. Currently, Akorn stock is trading higher than its 50-day moving average of $15.83, while the stock is trading lower than its 200-day moving average of $21.04. According to Mats Henriksson, chief executive of a Fresenius unit, Fresenius spent two years addressing the problems with one of its plants in India.

  • Fresenius Had Testing Woes Similar to Akorn, Unit Head Says
    Bloomberglast month

    Fresenius Had Testing Woes Similar to Akorn, Unit Head Says

    A Fresenius SE executive acknowledged his company has grappled with testing problems similar to those the German health-care company cited as a basis for pulling out of a $4.3 billion deal to buy U.S. generic drugmaker Akorn Inc. Mats Henriksson, chief executive of a Fresenius unit, testified Thursday that U.S. Food and Drug Administration inspectors in 2013 questioned drug-injection testing and test-result storage at one of the firm’s plants in India. It took the company two years to address those problems, Henriksson told Delaware Chancery Judge Travis Laster.

  • Akorn CEO Says Fresenius Is Using Smear Campaign to Cancel Deal
    Bloomberglast month

    Akorn CEO Says Fresenius Is Using Smear Campaign to Cancel Deal

    Akorn Inc.’s top executive complained Fresenius SE officials are unfairly smearing his firm’s reputation as the German company tries to pull out of $4.3 billion deal to to buy the generic drugmaker. Raj Rai, Akorn’s chief executive officer since 2010, told a judge Tuesday Fresenius’s claims that flaws in the company’s computer system led to fraudulent test results aren’t true. Akorn says that Fresenius is using minor mistakes to create a pretext for backing out of the the $34-per-share buyout.

  • Lax Drugmaker Computer Security Linked to Deal Cancellation
    Bloomberglast month

    Lax Drugmaker Computer Security Linked to Deal Cancellation

    John Avellanet, a consultant Akorn hired in 2016 after regulators questioned its operational procedures, discovered executives had little security control over the pharma company’s computer system and that raised doubts about the integrity of its record-keeping, said Lewis Clayton, a lawyer representing Fresenius SE in a trial over the failed merger. Akorn shares fell as much as 4.6 percent, the most intraday since May 3. Fresenius officials say Akorn’s testing miscues, along with a history of operational problems that drew warnings from the U.S. Food and Drug Administration, justified canceling the $34-per-share deal.

  • Akorn Was Warned About Problems Before Merger, Executive Says
    Bloomberglast month

    Akorn Was Warned About Problems Before Merger, Executive Says

    A consultant warned Akorn Inc. before its merger with Fresenius SE about production-line problems that raised questions about the integrity of data it provided to drug regulators, an Akorn executive testified as a trial over the failed $4.3 billion deal began. The consultant, hired to review procedures and operations at Akorn’s Decatur, Illinois, facility in 2016, found cameras recording drug vials coming down a line didn’t properly store pictures used to check cleanliness and safety, Kim Wasserkrug, an Akorn vice president, told Delaware Chancery Court Judge Travis Laster. Fresenius officials contend manufacturing problems at the Decatur plant and others, along with Akorn’s submission of allegedly phony data to federal regulators, are justifications for nixing the $34-per-share deal.

  • Is Fresenius SE & Co KGaA’s (FRA:FRE) 13.53% ROE Strong Compared To Its Industry?
    Simply Wall St.2 months ago

    Is Fresenius SE & Co KGaA’s (FRA:FRE) 13.53% ROE Strong Compared To Its Industry?

    The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and looking to gauge the potential return onRead More...

  • Does Fresenius SE & Co KGaA’s (FRA:FRE) PE Ratio Warrant A Buy?
    Simply Wall St.2 months ago

    Does Fresenius SE & Co KGaA’s (FRA:FRE) PE Ratio Warrant A Buy?

    Fresenius SE & Co KGaA (DB:FRE) is trading with a trailing P/E of 21.6x, which is lower than the industry average of 22.1x. While this makes FRE appear like aRead More...

  • Fresenius transfers inpatient rehabilitation business to Vamed unit
    Reuters2 months ago

    Fresenius transfers inpatient rehabilitation business to Vamed unit

    German healthcare group Fresenius said it was transferring its inpatient rehabilitation business from its private hospital operations to its Fresenius Vamed unit to better enable continued growth at the two businesses. "This will strengthen Fresenius Vamed's position as a leading provider of post-acute care in Europe. Fresenius Helios, meanwhile, will focus even more strongly on the acute care hospital business," the company said on Wednesday.

  • Fresenius transfers inpatient rehabilitation business to Vamed unit
    Reuters2 months ago

    Fresenius transfers inpatient rehabilitation business to Vamed unit

    German healthcare group Fresenius (FREG.DE) said it was transferring its inpatient rehabilitation business from its private hospital operations to its Fresenius Vamed unit to better enable continued growth at the two businesses. "This will strengthen Fresenius Vamed's position as a leading provider of post-acute care in Europe. Fresenius Helios, meanwhile, will focus even more strongly on the acute care hospital business," the company said on Wednesday.

  • Is Fresenius SE & Co KGaA (FRA:FRE) Undervalued?
    Simply Wall St.2 months ago

    Is Fresenius SE & Co KGaA (FRA:FRE) Undervalued?

    Today we’re going to take a look at the well-established Fresenius SE & Co KGaA (DB:FRE). The company’s stock saw a double-digit share price rise of over 10% in theRead More...

  • Was Fresenius SE & Co KGaA’s (FRA:FRE) Earnings Growth Better Than The Industry’s?
    Simply Wall St.3 months ago

    Was Fresenius SE & Co KGaA’s (FRA:FRE) Earnings Growth Better Than The Industry’s?

    After reading Fresenius SE & Co KGaA’s (DB:FRE) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in theRead More...

  • Reuters3 months ago

    Fresenius CEO defends cancelled Akorn deal

    FRANKFURT/BERLIN, May 18 (Reuters) - Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker. "It was certainly not an easy decision, but ultimately there was only one correct course," CEO Stephan Sturm, a former investment banker and experienced dealmaker, said at Fresenius' annual shareholder meeting in Frankfurt on Friday. Sturm served as chief financial officer before taking over as CEO in 2016 and has helped build the German company into a globally diversified healthcare group through a series of multi-billion dollar deals.

  • What Should You Know About Fresenius SE & Co KGaA’s (FRA:FRE) Future?
    Simply Wall St.3 months ago

    What Should You Know About Fresenius SE & Co KGaA’s (FRA:FRE) Future?

    Fresenius SE & Co KGaA’s (DB:FRE) released its most recent earnings update in December 2017, which revealed that the business benefited from a robust tailwind, leading to a double-digit earningsRead More...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of FRE.DE earnings conference call or presentation 3-May-18 12:00pm GMT

    Q1 2018 Fresenius SE & Co KGaA Earnings Call

  • Reuters3 months ago

    Corporate Europe senses relief as euro falls from peak

    The recent recovery in the dollar has raised hopes that currency turbulence for European corporates will now subside, after first quarter earnings took a hit from the stronger euro. Chemical groups Bayer on Thursday became the latest euro zone company affected by the strong euro, cutting its guidance and saying sales will likely fall in 2018. The euro has been on a steady rising path since mid 2017, reaching a more than three-year high against the dollar in February and capping gains for European stock markets.

  • Fresenius sees Akorn lawsuit dragging on into 2019
    Reuters3 months ago

    Fresenius sees Akorn lawsuit dragging on into 2019

    German healthcare group Fresenius SE (FREG.DE) said on Thursday its legal battle with Akorn (AKRX.O) over its canceled $4.7 billion takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro. Fresenius abandoned the merger agreement last month and on Wednesday alleged it uncovered "blatant fraud at the very top level" of the U.S. generic drugmaker. Akorn spokeswoman Jennifer Bowles said at the time the company categorically disagreed with the allegations and intended to enforce the merger agreement.

  • Reuters3 months ago

    Fresenius sees Akorn lawsuit dragging on into 2019

    German healthcare group Fresenius SE (FREG.DE) said on Thursday its legal battle with Akorn (AKRX.O) over its cancelled $4.7 billion (3.5 billion pounds) takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro. Fresenius abandoned the merger agreement last month and on Wednesday alleged it uncovered "blatant fraud at the very top level" of the U.S. generic drugmaker. Akorn spokeswoman Jennifer Bowles said at the time the company categorically disagreed with the allegations and intended to enforce the merger agreement.

  • Associated Press3 months ago

    Fresenius: 1Q Earnings Snapshot

    The Bad Homburg, Germany-based company said it had net income of 56 cents per share. Earnings, adjusted for non-recurring gains, were 49 cents per share. The dialysis services provider posted revenue of ...

  • Reuters3 months ago

    Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

    WILMINGTON, Del./NEW YORK (Reuters) - German healthcare group Fresenius (FREG.DE) alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc (AKRX.O) after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday. Fresenius abandoned the merger agreement last month, and Akorn has sued in Delaware Court of Chancery to try to hold Fresenius to the deal. Shares of Akorn slid nearly 15 percent on Wednesday to end at $12.55 per share.